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Abstract
A study of 69 paraffin-embedded ovarian tumor blocks revealed that CD3 infiltrating T cells positively
correlated with survival, melanoma-associated antigen A antigen expression correlated with poor outcome,
and high numbers of FoxP3 cells correlated with advanced disease. Identification of parameters associated
with survival will contribute toward the development of tests for early diagnosis and to the design of modern
therapies in ovarian cancer.
Aim: A knowledge of tumor-related antigens associated with survival of patients with ovarian cancer could contribute
toward the development of tests for early diagnosis and could provide targets for the design of novel immunotherapy
for advanced ovarian cancer. We conducted a pilot immunohistochemical study to determine a group of antigens in
ovarian tumor masses that correlate with survival. Methods: We studied T-cell subsets and tumor antigens on 69
cases of paraffin-embedded patient blocks to determine if any correlated with survival in this disease. These were
identified by staining for CD3, CD8, FoxP3, New York esophageal-1 (NY-ESO-1), melanoma-associated antigen
(MAGE) A, cyclin E, and intercellular adhesion molecule-1 (ICAM-1) antigens in tissue when using specific antibodies.
Results: Study patients had a median age of 58 years and an overall survival of 31%. Infiltrating CD3 T cells
correlated with improved survival of patients (P  .002, log-rank test). The frequency of cyclin E, ICAM-1, CD8, and
FoxP3 expressing cells were not statistically associated with survival. MAGE-A was expressed in 10 (45%) of 22
whole-tissue sections studied, and this expression correlated with decreased survival (P  .03, log-rank test). The
presence and frequency of FoxP3 infiltrating suppressor T cells was associated with high-stage disease (P  .02, 2
test; P  .03, Wilcoxon test). Conclusions: The significance of CD3 T cells in tumor tissue may be primarily
associated with an active antitumor immune response. MAGE-A family members may represent successful antigens
for immunotherapeutic targeting in ovarian cancer.
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iIntroduction
The immune system can recognize tumor-associated antigens and
elicit antibody and cellular responses to these antigens. Identification
of these antigens at the primary site of disease could provide specific
targets for improved diagnostic and immunotherapeutic measures.
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linical Ovarian & Other Gynecologic Cancer December 2012In ovarian cancer, the disease is usually detected in the later stages,
and, even though there is an initial response to frontline therapy,
disease-free survival remains low,1-6 thus, there is the need to under-
tand underlying biologic abnormalities and cellular targets in the
isease, to aid in the design of more effective immunotherapy.
Our interest is to identify molecules that may, in the future, be
sed as biomarkers for diagnostic or prognostic tools in ovarian can-
er or as new immunotherapeutic targets for the disease. In this
espect, these investigations were conducted to evaluate the associa-
ion between tumor-expressed antigens with stage of disease and
urvival. Current thinking supports the idea that focusing on identi-
ying a single antigen will most likely not be the route to understand-
ng the immune abnormalities in cancer.With this inmind, this pilot
tudy made a comprehensive investigation of different classes of an-
2212-9553/$ - see frontmatter © 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2012.09.001
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Atigens in ovarian cancer tissue including New York esophageal-1
(NY-ESO-1), melanoma-associated antigen (MAGE), intercellular
adhesion molecule-1 (ICAM-1), and cyclin E to reveal whether ex-
pression of these antigens was associated with overall survival of pa-
tients with ovarian cancer.
The antigens selected for study have been implicated in the prog-
nosis of cancer. For example, NY-ESO-1 (a cancer testis antigen)
expression is found in several types of cancer and only in a few normal
tissues, such as spermatogonia, oogonia, and placenta.7,8 The ability
of this antigen to elicit CD4 and CD8 T-cell responses or NY-
SO-1 antibody induction in different cancers with patients bearing
Y-ESO-1 antigen expressing tumors9-12 suggests that it may be a
andidate biomarker for this disease. The MAGE family of cancer
estis antigens consists of several antigens that are primarily restricted
o normal testes and placenta but that are expressed in several can-
ers.13-16 It is an immunogenic antigen, and, in cancer patients, both
T cell and serologic immune responses have been elicited to this
antigen.13,17-20
ICAM-1 is a glycoprotein of the immunoglobulin superfamily of
adhesion molecules. It is expressed on the surface of many cancer
cells. There are contrasting reports concerning the function of this
antigen in cancer.21-23 Cyclin E is a regulator of the cell cycle and
unctions at the G1-S checkpoint. The cyclin E-cdk2 complex reg-
lates entry into the S phase.24,25 Overexpression of cyclin E is found
n several tumors.26-28 In addition, we studied the degree of infiltrat-
ing T cells in ovarian cancer tissue. Effector T cells in tumor tissue are
becoming increasingly recognized as critical mediators of anticancer
immunity.29-33 In contrast, with the exception of a few reports,
oxP3 regulatory cells are associated with an unfavorable outcome in
ancer.34,35
The goal of this pilot study was to identify antigens in ovarian
cancer tissue and to determine if they alone or in combination with
infiltrating lymphocytes were associated with overall survival. In ad-
dition, we studied unstaged disease and low-stage cancer to deter-
mine whether patterns of antigen expression are significantly differ-
ent with disease stage.
Patients and Methods
Patients and Tissue Samples
Ovarian cancer tissue paraffin embedded blocks were chosen for
study from archived samples of patients at LoyolaUniversityMedical
Center, Chicago, Illinois, after appropriate institutional review
board for the protection of human subjects approval. Patients se-
lected underwent surgery between 2002 and 2007. Of 69 patients
studied, groups consisted of stage I, II, III, and IV, or borderline
ovarian cancer as well as endometrioid serous papillary, fallopian
tube, and peritoneal cancers (Table 1). Forty-seven tissue sections
from patients were embedded as tumor tissue arrays (TMA), with an
average of 5 patient sections on each slide. Twenty-two patient tissue
blocks consisted of a single patient section on each slide. Control
tissues used were benign ovarian cysts, tonsils, and testes.
Preparation of Tissue
Slides with paraffin-embedded tissue sections (4 m) were depar-
affinized in xylene and rehydrated in graded alcohols. Sections were
boiled in a pressure cooker for 5 minutes in antigen retrieval agent at
one times concentration of (1 X) Reveal Decloaker (RV1000G1,Biocare Medical, Concord, CA) for all antigens except ICAM-1,
which was boiled in 1 X Borg Decloaker (BD1000G1, BiocareMed-
ical). Sections were immersed in 0.4% hydrogen peroxide in 1 
Dulbecco’s phosphate buffered saline (DPBS; Gibco [Life Technol-
ogies, Gaithersburg, MD]) in a coplin jar for 20 minutes. Tissue was
blocked with 10% goat serum (S1000, Vector Laboratories, Burlin-
game, CA) or 10% horse serum (S2000, Vector Laboratories), fol-
lowed by the Avidin/Biotin blocking system (SP2001, Vector
Laboratories).
Immunohistochemical Staining
Primary antibodies in 5% blocking serum was added to sections
overnight. Mouse anti-human monoclonal antibodies were used as
follows: cyclin E (13A3, sc56310, used at 1:400 dilution), NY-
ESO-1 (E978; sc53869), andMAGE-A (6C1; SC 20,034; detecting
MAGE-A1, 2, 3, 4, 6, 10, and 12) were purchased from Santa Cruz
Biotechnology, Santa Cruz, CA. Staining was also performed for
FoxP3 (236 A/E7; ab20034, 1:1600 dilution, Abcam, Cambridge,
MA), CD3 (F7.2.38; 1:1000 dilution, Dako, Glostrup, Denmark)
and CD8 (C8/144B; 1:100 dilution, Cell Marque, Rocklin, CA).
Rabbit antihuman monoclonal antibodies used were ICAM-1
(EP1442Y, NB57106; 1:400 dilution, Novus Biologicals, Littleton,
CO), and CD4 (SP35 mAb M3554; 1:100 dilution, Spring BioSci-
ence, Pleasanton, CA).
The next day, a biotinylated secondary antibody for peroxidase or
alkaline phosphatase was added (30 minutes, PK 6101, rabbit im-
munoglobulin [Ig] G, PK 6102, mouse IgG or AP5100, mouse IgG;
Table 1 Patient Classificationa
Diagnosis No.Patients FIGO Stage
High/Advanced Stage: 49 Patients
Ovarian serous papillary carcinoma 39 III and IV
Endometrial papillary serous carcinoma 1 III
Primary peritoneal serous carcinoma 9 Advanced
Low Stage: 10 Patients
Ovarian serous papillary carcinoma 6 I and II
Ovarian mixed transitional and serous
cell carcinoma 1 II
Mucinous carcinoma 1 1
Primary fallopian tube serous carcinoma 1 I
Endometrial papillary serous carcinoma 1 I
Borderline: 8 Patients
Ovarian borderline serous tumor 8 Bb
Benign: 2 Patients
Ovarian benign serous tumor 2 Benign/B
Overall survival was based on the time of diagnosis and the time of last follow up.
Profile: Total number of patients, 69; age range, 26-86 y; median age, 58 y.
Survival information was calculated by using patients with stage I, II, III, IV, advanced disease:
n 59. Median overall survival: 35.63 mo (95% CI, 25.9-61.7 mo).
bbreviation: FIGO International Federation of Gynecology and Obstetrics.
a Histologic stage is shown for 69 patients with gynecologic tumors.
b B represents borderline tumor.Vector Laboratories kits), followed by an Avidin and biotinylated
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80 Chorseradish peroxidase macromolecular complex (Avidin Biotinyl-
ated enzyme Complex [ABC]) reagent, or an Avidin DH and bio-
tinylated alkaline phosphatase H complex reagent (30minutes) from
the Vector Laboratories kits as above. Slides were developed in chro-
mogens diaminobenzidine (SK4100), Vector NovaRED (SK4800),
or Vector Red alkaline phosphatase substrate kit 1 SK5100. Tissue
was counterstained with hematoxylin and rehydrated in alcohols and
in xylene. Sections were mounted in Vectamount (H-5000, Vector
Laboratories).
Evaluation of Antigens in Tissue
Each patient section was evaluated for the location and extent of
positive staining on tumor cells and on infiltrating lymphocytes in
sections. For CD3 and FoxP3, the numbers of peri- and intratumoral
infiltrating lymphoid cells were quantitated by using a numerical
score of 0-3 (0, rare positive cells; 1,10/HPF; 2, 10-40/HPF; and
3, 40/HPF). To determine the extent of CD8 staining, the per-
centage of CD8-strong positive staining lymphoid cells was esti-
mated. This number was multiplied by the numerical score on the
corresponding CD3 stain (0-3) to generate a composite score (range,
0-300). NY-ESO-1, MAGE-A, ICAM-1, and cyclin E were scored
on a scale of 0-3 (0,10%; 1, 10%-25%; 2, 25%-50%; 3,50%).
Because the tissue was culled largely fromTMAs, whereinmany of
the cases contained densely packed epithelial cancer without inter-
vening stroma, our scoring system did not separate stromal and epi-
thelial staining in the sections. For MAGE-A detection, there was an
obvious difference in scoring between TMAs and whole-tissue sec-
tions, in which case, we used the full tissue-section scoring in our
analysis.
Data Analysis
The Fisher exact test or the 2 test was used to determine the
ssociation between antigen expression (present or absent) and tu-
or stage (high or low). Wilcoxon rank sum tests were used to
ompare the degree of expression of each antigen studied (score 0-3),
r percentage of lymphocyte infiltrate, stratified by tumor stage.
ased on the scoringmethod, CD8was used as a continuous variable
n analysis. Kaplan-Meier curves were generated to estimate correla-
ion between antigen expression and overall survival, with signifi-
ance determined by the log-rank test. The level of significance in
nalysis was indicated by P  .05. Cox proportional hazard models
ere fitted to determine whether the presence of infiltrating lympho-
ytes (CD3 or FoxP3) combined with other antigens (NY-
SO-1, MAGE-A, ICAM-1, or cyclin E) studied in tumor tissue
ere associated with survival.
Results
Patient Clinical Profiles
We studied 69 patients, between 26 and 86 years of age, with a
median age of 58 years, with ovarian disease. Of the 69 patients, 38
(69%) were presented with advanced ovarian serous papillary carci-
noma stage III disease, and 1 patient at stage IV. Other patients had
low-stage (stage I, stage II) or borderline disease (Table 1). At the
time of the last follow-up, 44 (69%) had died of the disease and 20
(31%) patients were alive. Five patients were lost to follow-up.
Twenty-six (41%) of 64 patients were alive at 5 years after diagnosis.
Themedian overall survival of patients with of stage 1, II, III, IV, and
linical Ovarian & Other Gynecologic Cancer December 2012advanced cancer (n  59) was 35.63 months (95% CI, 25.9-61.7
months). Patients with borderline disease were not included in sur-
vival analysis.
Distribution of ICAM-1, NY-ESO-1, MAGE-A, and
Cyclin E in Ovarian Cancer Tissue
To identify tumor-related antigens that are associated with sur-
vival, we examined normal and malignant tissue for the expression of
NY-ESO-1, MAGE-A, ICAM-1, and cyclin E. In ovarian cancer,
NY-ESO-1 stained only a small proportion of tumor cells in all cases
and notably, positive cells were stained in the cytoplasmic (Figure
1A, inset) and/or nuclear compartments (Figure 1A). In addition,
normal control ovarian tissues did not stain for NY-ESO-1 (not
shown). Cyclin E staining was restricted to the nuclear compartment
in tumors. A variable proportion of tumor cells stained with varying
intensity for this antigen (Figure 1B). MAGE-A staining was typi-
cally focal but distinct and restricted to tumoral cell cytoplasm in all
cases stained (Figure 1C). In addition, tumoral nuclear staining was
apparent in 2 cases. Stromal staining for MAGE-A was never en-
countered. In tumors with a distinct papillary configuration,
ICAM-1 staining was noted only on the apical membrane, whereas
tumor that displayed a more solid cytoarchitecture showed addi-
tional cytoplasmic staining (Figure 1D). In benign ovarian tissues,
staining was restricted to the vasculature, without any staining of the
stromal tissues (not shown).
Characterization of Lymphocytes in Tumor Tissue
To understand the relationship between the immune infiltrate and
survival, staining was performed to determine the presence and dis-
tribution of CD3, CD4, CD8, and FoxP3 cells (Figure 2A-D). For T
lymphocytes, we primarily evaluated CD3, CD8, and FoxP3, be-
cause CD68 macrophages may also stain with the CD4 antibody.
In some ovarian cancer sections, clusters of CD3 cells were seen in
the perivascular areas within the tumor supporting stroma or over-
lapped with tumor cells as an intratumoral infiltrate (Figure 2A). We
found that CD8 cells spatially correlated in distribution with the
D3 cells. Typically, only a proportion of the lymphoid cells
tained with CD8 in the stromal perivascular areas of tumor (Figure
C). Compared with CD3 and CD8, a much smaller proportion of
ymphoid cells stained for FoxP3, and these occurred as scattered
ells amid the tumor (Figure 2D).
Occurrence of Antigens in Tumor Tissue
NY-ESO-1 was primarily present in stage III ovarian cancer in
comparison with other patient groups. ICAM-1 and cyclin E were
ubiquitously expressed in most groups of cancer patients. CD3 and
CD8 cells were identified in most sections studied. The distribution
of MAGE-A cells in TMA sections was different when compared
with whole-tissue sections inasmuch as only 3 of 39 TMAs exhibited
positive staining for MAGE-A. In whole-tissue section, 10 (45%) of
22 patient tumor sections were positive for MAGE-A antigen stain-
ing. This is understandable given the marked spatial heterogeneity of
MAGE-A staining, which is better captured by using whole sections.
Our analysis shown for MAGE-A is based on the full-tissue sections
only as this is representative of other MAGE antigen staining in the
literature.36,37
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Patrick J. Stiff et alFoxP3 positive cells were present in 35 (74%) of 47 patients with
stage III, IV, and advanced cancer, whereas these cells were present in a
lower percentage of patients in other groups (Table 2). The presence of
FoxP3 infiltrating cells was directly associated with high-stage cancer (P
 .02, 2 test) (Table 3). We then asked whether the frequency of
oxP3 infiltrating cells also correlated with this parameter. Analysis by
he Wilcoxon rank sum test revealed that the level of FoxP3 expressing
ells (score 0-3) was significantly higher in stage III, IV, and advanced
isease in comparison with patients unstaged or with stage I or II (P
03) (Table 4). Apart fromour findings for FoxP3 expression anddisease
Figure 1 Expression of Antigens in Tumor Tissue. Ovarian Tum
Antibodies and a Biotinylated Secondary Antibody. Te
Esophageal-1 (NY-ESO-1), Melanoma-Associated Anti
Control Slides Were Benign Ovarian Tissue, or No Pri
a Trabecular Growth Pattern That Shows Evidence of
(inset). (B) Cyclin E Nuclear Staining Apparent in Mos
Intercellular Adhesion Molecule-1 (ICAM-1) Expressio
Apical Staining Pattern, Whereas More Solid Areas Sh
Typically Focal but Distinct and Restricted to Tumora
Was Also Apparent in 2 Cases. All Panels are at 40
NovaRED (red/brown), Diaminobenzidine (brown) Was
Kit 1 SK5100 (pink) Was Used to Detect MAGE-A. Tis
A
Ctage, there was no significant difference between the level of expressionscore 0-3) of any other antigen studied and tumor stage (P  .05,
ilcoxon rank sum test), neither was there any significant association
etween the presence and absence of these antigens and tumor stage (P
.05, Fisher exact test or 2 test; not shown).
Correlation Between Expression of Antigens and
Overall Survival
Kaplan-Meier curves and log-rank tests were performed to esti-
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82 C(I and II) and high-stage (III) ovarian cancer (Figure 3A). Impor-
tantly, CD3 T cells in tumor correlated with improved survival of
patients (P  .002, log-rank test) (Figure 3B).
NY-ESO-1 was present in 13 (27%) of 48 patients with stage III
Figure 2 Immunostaining of T Lymphocytes in Tumor Tissue. P
(A). CD3 Primary Antibody, Showing a Brisk Intratum
CD4 (B) and on CD8 (C). Few Scattered CD4 T Cells
the T Cells Shows Strong Nuclear FoxP3 Expression.
NovaRED (red/brown) for CD3 and CD8 and Diaminob
With Hematoxylin (blue/purple)
A
C
Table 2 Comparison of the Presence of Antigens in Different S
NY-ESO-1 MAGE-A
Stage III/Advanced Ovarian Cancer 13/48 (27)b 10/18 (56)
Low Stage Cancer (stage 1, II) 3/18 (17) 0/4 (0)
Borderline Cancer 1/8 (13) 0/0 (0)
Benign Disease 0/2 (0) 0/0 (0)
a Patient sections were stained to detect antigens as above; a summary of antigens present in tum
that stained positive for each antigen is shown.
b The numbers in brackets shows the percentage of patients with tissue staining positive for eaovarian cancer and showed no association with survival (P  .59, a
linical Ovarian & Other Gynecologic Cancer December 2012log-rank test). Antigens cyclin E (P  .26, log-rank test) and
ICAM-1 (P .42, log-rank test), and CD8 (P .18, log-rank test)
Figure 3C) and FoxP3 cells (P .62, log-rank test) were present in
high number of patients (Table 2) but were not statistically associ-
fin-Embedded Ovarian Cancer Tissue Staining is Shown for
erivascular T-Cell Infiltrate With Similar Staining Patterns on
Apparent in the Luminal Aspect in This Case. (D) A Subset of
anels Are 40 Magnification. Chromogens Were Vector
ine (brown) for CD4 and FoxP3. Tissue Was Counterstained
s of Cancera
AM-1 Cyclin E CD3 CD8 FoxP3
/49 (86) 36/47 (77) 42/48 (88) 44/48 (92) 35/47 (74)
10 (90) 9/10 (90) 9/10 (90) 9/10 (90) 5/10 (50)
/8 (88) 5/8 (63) 8/8 (100) 7/8 (88) 3/8 (38)
/2 (50) 2/2 (100) 2/2 (100) 2/2 (100) 1/2 (50)
e as determined based on pathologic observations made on each section; the number of sections
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Patrick J. Stiff et alcorrelated with decreased patient survival (P  .03, log-rank test)
Figure 3D).
We further asked whether the presence of infiltrating T cells
CD3 or FoxP3) together with other antigens expressed in tumor
issue (NY-ESO-1, ICAM-1, cyclin E, or MAGE-A) were associated
ith survival in patients with ovarian cancer. From this, we found
hat CD3 infiltrating T cells were the significant overriding factor
Table 3 Expression of MAGE-A and FoxP3 in Different
Stages of Cancera
Variable Level
Tumor Stage
Total P Value, FisherExact TestLow
(B, I, II)
High
(III, IV)
FoxP3 0 10 (45) 12 (55) 22 .02b
0 8 (19) 35 (81) 43
Total 18 47 65
MAGE-A 0 4 (33) 8 (67) 12 .10c
0 0 (0) 10 (100) 10
Total 4 18 22
The numbers in brackets shows the percentage of patients with tissue staining positive for each
antigen with tumor stage.
Abbreviations: ICAM-1  intercellular adhesion molecule-1; MAGE  melanoma-associated
antigen; NY-ESO New York Esophageal-1.
a Ovarian cancer tissue was stained to detect cells staining positive for MAGE-A, FoxP3 (shown
above), NY-ESO-1, ICAM-1, cyclin E, CD3 and CD8 (not shown); scoring of the presence (0)
of antigens in tissue was performed; correlations between the presence of each antigen and
low-stage disease (borderline cancer; B, stage I and II) and high-stage disease (III, IV, and
advanced stage) were determined by 2 testb or the Fisher exact testc; only FoxP3 infiltrating
cells showed association with tumor stage (P.02).
Table 4 Relationship Between the Frequency of Antigen
Expression and Tumor Stagea
Variable Level
Tumor Stage
Total P Value,Wilcoxon TestLow
(B, I, II)
High
(III, IV)
MAGE-A 0 4 (33) 8 (67) 12 .08
1 0 2 (100) 2
2 0 6 (100) 6
3 0 2 (100) 2
Total 4 18 22
FoxP3 0 10 (45) 12 (55) 22 .03
1 6 (22) 21 (78) 27
2 1 (8) 12 (92) 13
3 1 (33) 2 (67) 3
Total 18 47 65
The numbers in brackets shows the percentage of patients with tissue staining positive for each
antigen across variables (level of expression and tumor stage).
Abbreviations: ICAM-1  intercellular adhesion molecule-1; MAGE  melanoma-associated
antigen; NY-ESO New York Esophageal-1.
a Immunohistochemical detection of antigens was performed and the frequency (level) of cells
positive for MAGE-A, FoxP3 (shown above), NY-ESO-1, ICAM-1, cyclin E, CD3, and CD8 (not
shown) scored (0-3, as described in the Methods section above); correlations were determined
between the frequency of positive cells and high (III, IV, and advanced) and low (borderline; B,
I, and II) stage cancer; only the frequency of FoxP3 cells correlated with disease stage (P .03,
Wilcoxon test).ssociated with survival (Cox proportional hazard models for CD3; sazard ratio 0.27, P  .05) (Table 5). In our tissue samples, we did
not find the ratio of CD3-FoxP3 to be associated with survival ( P
.05, Cox models) (Table 5).
Discussion
These investigations addressed the presence of tumor-related an-
tigens and T cells in ovarian cancer tissue and their correlation with
patient overall survival. The goal was to screen a small group of
patients in a pilot study for selected antigens to determine which
antigens investigated are promising to study in a larger cohort mea-
suring survival. In ovarian cancer, the preclinical stage is short and
the disease is diagnosed in the later stages when it has already spread
to areas of the abdomen. Due to the severity of this disease, we would
like to understand whether there are certain antigens present in the
tumor mass that correlate with survival. An answer to this question,
we believe, will, in the future, lead investigations into novel diagnos-
tic and effective immunotherapeutic measures.
Of the antigens studied, NY-ESO-1 is a tumor-specific antigen of
the cancer testis group that is highly immunogenic.7-12,38 We found
Y-ESO-1 in 13 (27%) of 48 patients with stage III or advanced
varian cancer, but the distribution was slightly lower in low-stage
ancer (17%; 3 of 18 patients). In our pilot study, expression of this
ntigen on tumor cells did not correlate with survival. Investigations
ere further conducted on another cancer testis antigen family,
AGE-A,13-16 which is believed to be immunogenic in several can-
cers.13,17-20 The association of MAGE-A expression with decreased
urvival as we have demonstrated here makes a case for the use of
AGE-A as an immunotherapeutic target in patients with ovarian
ancer whose tumors express this antigen. In this respect, clinical
rials have been initiated for several cancers by using MAGE
s a target antigen (eg, http://ClinicalTrials.gov Identifier:
CT00706238; metastatic cutaneous lymphoma, NCT00257738;
quamous cell carcinoma of head and neck, NCT00090493; multi-
le myeloma, and a vaccine trial in non–small-cell lung cancer by
laxoSmithKline).
Cyclin E is a poor prognostic factor in breast cancer, non–small-
ell lung cancer and gastric cancer.26-28 One study, however, showed
hat low expression of cyclin E resulted in longer survival in ovarian
ancer in patients who received a combination of cisplatin and Taxol
Bristol-Myers Squibb, Princeton, NJ).39 In our study, cyclin E was
present in 45 (79%) of 57 patients with stage I, II, and III or ad-
vanced ovarian cancer. We did not find a correlation between overall
survival and cyclin E expression on tumor cells but will further in-
vestigate this antigen in a larger group of patients.
The immune infiltrate in tumors consists of many cell types, such as
antitumor effector cells (CD8T cells, and Th1 cells) as well as tumor-
romoting suppressor cells. In some cancers, a balance between these 2
roups of immune cells may predict prognosis, the efficacy of chemo-
herapy, and immunotherapy. The importance of T cells in tumor has
ecently been highlighted in other studies.29-33,40 For example, patients
diagnosed with stage I tumors (andminimally invasive disease) with few
infiltratingTcells had a similar outcome topatientswithmetastatic stage
IV cancer,30 which indicates that the preeminent factor in survival was
ot the stage of cancer at the time of diagnosis. Consistent with these
eports, our results did not find a correlation between stage of cancer and
urvival.
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84 CThe influx of T cells into tumors is under the influence of several
factors.22,41,42 For example, the presence of the endothelin B recep-
or (ET BR) is associated with the absence of tumor infiltrating lym-
hocytes.22 ET BR is expressed in tumor tissue, including ovarian
umors.43 ET BR causes upregulation of nitric oxide (NO) synthases,
nd NO release. NO reduces both the expression of ICAM-1 and
CAM-1 clustering, and limits T-cell adhesion to the endothe-
ium.22,44,45 In our study, ICAM-1 was expressed in 58 (87%) of 67
cases of ovarian cancer tissue.We did not find a statistical correlation
between ICAM-1 and survival in this pilot study.
In our study, the presence of CD3 T cells in tumors correlated
with overall survival. It is possible that these cells, which advance to
the tumor beds, may provide antitumor immunity and may have
migrated into the tumor to downregulate immune suppressive pa-
rameters induced by other cell types, such as FoxP3 T regulatory
cells. In other reports, tumor infiltrating T lymphocytes as well as the
ratio of T lymphocytes to FoxP3 were associated with survival.46 The
resence and extent of FoxP3 T cells was associated with advanced
ancer. In the event that cancer patients with advanced disease also
Figure 3 Patients Overall Survival Curves. (A) Kaplan-Meier Su
Low-Stage (I and II) Ovarian Cancer (n  59). (B) Ka
MAGE-A (MAGE; n  22). The Low Expression of CD8
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Cave high circulating levels of FoxP3 expressing T cells, this param-
linical Ovarian & Other Gynecologic Cancer December 2012ter may be a useful prognostic factor in patients with late-stage
ancer.
In conclusion, we demonstrated that CD3 T cells in ovarian can-
er tissue was associated with prolonged overall survival of patients
nd that MAGE-A was associated with poor survival. This provides
he basis for future studies to identify associations between other
ancer testis antigens and survival in ovarian cancer, the potential
mmunogenicity of these antigens, and to evaluate the possibility of
argeting these antigens as immunotherapeutic agents. Other studies
hat address the strategic location of T cells in proximity to cancer
ells and their phenotype, including whether they are memory cells
CD8/CD3CD45RO), will shed light on the consequences of
the immune infiltrate and provide critical insight to the antitumor
immune response in ovarian cancer.
Clinical Practice Points
● Ovarian cancer is one of the most lethal gynecologic diseases. It is
generally diagnosed at the stage of advanced disease pathology at
which time it has spread to areas of the abdomen. Current thera-
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Waspies for advanced disease are not sufficiently effective, and, hence,
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Patrick J. Stiff et althe 5-year survival of these patients is approximately 20%. Early
diagnosis and novel targeted therapies will positively impact out-
come.
● To understand the underlying factors, we conducted immunohis-
tochemical studies investigating infiltrating immunocompetent
and suppressor T cells, and tumor-associated antigens and their
correlation with patient survival. Studies were conducted on 69
paraffin-embedded tumor tissues. Antibodies were used to study
immunoreactivity in tissue for CD3, CD8, FoxP3, NY-ESO-1,
MAGE-A, cyclin E, and ICAM-I. The results showed that CD3
tumor infiltrating T cells did not vary with stage of disease, but
they were a significant predictor of prolonged survival. The expres-
sion of MAGE-A was identified primarily in advanced disease and
was associated with poor outcome. The presence of high levels of
FoxP3 tumor infiltrating cells correlated with a diagnosis of ad-
Table 5 Summary of Cox Model to Determine the
Association With Combinations of Antigens and
Survivala
Model Parameter Level Estimate P Value HazardRatio
1 CD3 >0 vs. 0 –1.30937 .0034 0.27
NY-ESO-1 0 vs. 0 0.21193 .5388 1.236
2 CD3 >0 vs. 0 1.28872 .0134 0.276
ICAM-1 0 vs. 0 0.10865 .8264 0.897
3 CD3 >0 vs. 0 1.30117 .0036 0.272
Cyclin E 0 vs. 0 0.00228 .9952 1.002
4 FoxP3 0 vs. 0 0.05784 .8628 1.06
NY-ESO-1 0 vs. 0 0.20067 .5585 1.222
5 FoxP3 0 vs. 0 0.19674 .5658 1.217
ICAM-1 0 vs. 0 1.07726 .015 0.341
6 FoxP3 0 vs. 0 0.04343 .8984 1.044
Cyclin E 0 vs. 0 0.07335 .8477 1.076
7 CD3 2 vs. 1 0.88658 .3514 0.412
3 vs. 1 0.60852 0.544
MAGE-A 0 vs. 0 1.54216 .021 4.675
8 CD3 >0 vs. 0 1.23199 .019 0.292
NY-ESO-1 0 vs. 0 0.22366 .5197 1.251
ICAM-1 0 vs. 0 0.14385 .774 0.866
9 CD3/FoxP3 0.36501 .2471 1.441
10 MAGE-A 1 vs. 0 1.58578 .1847 4.883
2 vs. 0 1.10878 3.031
3 vs. 0 1.24271 3.465
Data in bold indicates models in which CD3 is associated with survival.
Abbreviations: ICAM-1  intercellular adhesion molecule-1; MAGE  melanoma-associated
antigen; NY-ESO New York Esophageal-1; Neg negative; Pos positive.
a Cox proportional hazard models were fitted to determine whether combinations of antigens
stained in ovarian tumor tissue of patients (n 59) (stage I, II, III, and IV and advanced disease)
was associated with survival. The parameters and/or categories tested are indicated. In model
1 for example, both CD3 (Pos/Neg; 0 vs. 0) and NY-ESO-1 (Pos/Neg) were included to
examine their effect on survival. After controlling for NY-ESO-1, CD3 is still significant (P 
.003; hazard ratio 0.270). The hazard rate of CD3 Pos is 27% that of CD3 Neg.vanced disease.● Patients with high numbers of CD3 infiltrating cells in their tu-
mors at the time of diagnosis may have the ability to elicit a more
effective antitumor response and may respond more favorably to
standard therapy and immunotherapy regimens than patients with
fewer infiltrating T cells.
● In ovarian cancer, the design of immunotherapy that targets
MAGE-A may be a useful strategy to improve therapeutic benefits
for advanced-stage cancer in patients whose tumors express this
antigen.
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